858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.
IPO/Acquired
NASDAQ: AVEO
Acquired by LG Chem
Commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
Abcuro is a clinical-stage company developing Ulviprubart, a FIC anti-KLRG1 antibody in Ph2/3 pivotal trials for Inclusion Body Myositis (IBM).
Biopharmaceutical company focused on innovative small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders
Acquired
Acquired by Johnson & Johnson
Developer of Balloon Sinuplasty
Acquired
Acquired by Nicox S.A.
Specialty pharmaceutical company focused on the development of therapeutics to treat front of the eye diseases
Acrivon is developing best-in-class targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon’s unprecedented patient selection method represents a paradigm change in precision oncology drug development.
Biopharma company developing affinity enhanced T cell receptor (TCR) engineered T cells to treat hematologic and solid tumor cancers.
IPO/Public
NASDAQ/SIX: ADXN
Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders.
Acquired
Acquired by Eli Lilly & Company
China-based, fabless semiconductor company
German-domiciled and NASDAQ-traded company developing a variety of immuno-oncology therapeutics.
An innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases.
Ajax is a biotechnology company that focuses on cardiovascular devices
Biotechnology company developing advanced therapies for autoimmune and inflammatory diseases.
IPO/Acquired
NASDAQ: AKUS
Acquired by Eli Lilly and Company
Akouos is a biotechnology company focused on restoring and preserving hearing.
Biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals
Acquired
Acquired by Concentra Biosciences
Biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.
Ultra-sustained analgesic products for post-surgical pain management.
Adaptive, closed-loop neuromodulation device targeting the pudendal nerve to treat mixed urinary incontinence.
Oral pharmacological chaperone protein therapies to address diseases that result from protein misfolding
Acquired
Acquired by Pfizer
Developing a novel class of drugs to treat life‐threatening systemic fungal infections.
Acquired
Acquired by Medtronic
Products for the endovascular surgery market
Annexon Biosciences is leading the development of therapeutic products that halt the progression of complement-mediated neurodegeneration. Annexon’s antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in the loss of nerve connections and inflammation.
Acquired
Acquired by Microvena
Novel device and procedure for preventing cardioembolic stroke in patients with Atrial Fibrillation
IPO/Acquired
NASDAQ: ACLX
Acquired by: GILEAD
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
Focused on the discovery and development of novel therapeutics acting exclusively in the gastrointestinal tract and devoid of systemic exposure
IPO/Acquired
NASDAQ: ASPM
Acquired by Covidien
Noninvasive anesthesia monitoring systems
Clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need.
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation of small-molecule and ADC oncology therapies for patients.
AviadoBio is a biotechnology company developing transformative gene therapies for neurodegenerative disorders using a novel neuroanatomy-led approach to drug delivery.
Basalt is a tool that integrates into EMRs to help clinical and admissions teams make faster, more consistent decisions by pulling together patient data, applying clinical criteria, and surfacing what actually matters without manual chart digging.
Acquired
Acquired by Life Technologies
Distributor of enzymes and other products allowing manipulation of DNA
Black Diamond discovers and develops next-wave precision cancer medicines to treat patients with genetically defined cancers driven by oncogenes activated by allosteric mutations.
Brenig is a small molecule drug development company that utilizes an AI/ML approach via a partnership with Expert Systems Inc., a drug accelerator that has spawned multiple best-in-class clinical candidates across multiple therapeutic areas.
Acquired
Acquired by Boston Scientific
Medical device company pioneering solutions to recanalize chronic total occlusions
A Basel, Switzerland and Boston, MA-based biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines with the potential to cure serious human genetic diseases
IPO/Acquired
NYSE: CTIC
Acquired by Sobi
CTI BioPharma develops drugs that leverage the its expertise in blood-related cancers to address unmet medical needs and find therapies that are less toxic.
Acquired
Acquired by Covidien
Developing a paclitaxel-coated drug-eluting balloon (DEB) for use in treating peripheral vascular disease
Rheos™ Baroreflex Hypertension Therapy System for treatment of refractory hypertension
IPO/Acquired
NASDAQ: CADX
Acquired by Mallinckrodt
Hospital-focused biopharmaceutical company
IPO/Acquired
NASDAQ: CTSI
Guidant; Boston Scientific
Instruments and procedures to advance coronary artery bypass graft surgery
Medical device company that is developing a catheter-based neuromodulation solution for the treatment of acute decompensated heart failure (ADHF).
IPO/Acquired
NASDAQ: CVIS
Boston Scientific
Ultrasonic imaging catheter and instrument system for diagnosis of coronary, peripheral and carotid arteries
Acquired
Acquired by Bristol Myers Squibb
Discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease
Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases.
Acquired
Acquired by Cartiva; Wright Medical Group
Medical device company developing innovative solutions for patients with osteoarthritis and cartilage damage
Acquired
Acquired by Wright Medical
Developer of innovative products for the treatment of cartilage injuries and osteoarthritis
IPO/Acquired
NASDAQ: CASC
Acquired by Seattle Genetics
Clinical-stage biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer.
Biopharmaceutical company focused on drugs to treat CNS disorders by targeting neuronal nicotinic receptors
Minneapolis-based clinical stage biotechnology company focused on the development of molecularly targeted drugs for cancer.
Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development.
Clinical stage biopharmaceutical company focused on the development of drugs to treat diseases of the central nervous system
Global preclinical research and clinical specialty testing provider driving excellence in oncology drug development programs.
Acquired
Acquired by Shanghai Pharmaceuticals
Provider of pharmaceuticals, medical supplies and health care information technologies to China's fast-growing healthcare services industry
ChromaCode uses patented mathematical methods and algorithms to enrich signal processing from the most popular life science instrumentation. Their initial products enable high multiplexing of biological tests using existing real-time PCR instruments at a very low cost.
Discovering and developing novel small molecule therapies for difficult-to-treat cancers
IPO/Acquired
NASDAQ: CMTA
Acquired by Ipsen
Biopharmaceutical company focused on developing treatments for rare diseases
Focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets
A next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases.
Acquired
Acquired by Teva Pharmaceuticals
Focused on development of biotherapeutics for treatment of cancer, heart disease
Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to make every pregnancy around the world safer.
Developing disease-modifying nitro fatty acid platform technology for patients with fibrosis and inflammation-associated orphan diseases.
Products for the reproductive health market
CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world.
Acquired
Acquired by Horizon Therapeutics
Treatment of Systemic Sclerosis.
DOTS (Detection On The Spot) is a health tech company creating a revolutionary diagnostics platform with consumer and industrial applications that is changing the field of point of care detection.
IPO/Acquired
NASDAQ: DERM
Acquired by Lilly
A company focused on developing and commercializing innovative new therapies in dermatology
Acquired
Acquired by Schering AG
Therapeutic peptides and imaging agents for thrombus, atherosclerosis and inflammation
Synthetic peptides for treatment of allergies and asthma
Acquired
Protein Design Labs
Pharmaceutical company focused on the quality of therapeutics in the acute-care hospital setting
Biotech company aimed at creating the next generation of genetic medicines.
IPO/Public
St. Jude Medical
Tools for diagnosing and treating cardiac arrhythmias.
Acquired
Acquired by Boston Scientific
NexStent for next-generation carotid artery stenting
Acquired
Acquired by Aerie Pharmaceuticals
Biotechnology startup focused on developing ophthamology products
Acquired
Acquired by Alkermes
Polymer based drug delivery systems for therapeutic proteins
Acquired
Acquired by Ajax Health LLC
EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics, Inc.) is a medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB.
IPO/Acquired
NASDAQ: EPZM
Acquired by Ipsen
Biopharmaceutical company that is creating innovative drugs for major diseases based on important discoveries emerging from the field of Epigenetics
A clinical-stage biopharma company based in Lyon, France
Acquired
Acquired by Incyte
Escient is a clinical-stage pharmaceutical company focused on discovering and developing first-in-class therapies to address serious, unserved medical needs. The company is led by an experienced team with specific expertise in GPCR drug discovery and development. Escient's pipeline consists of two novel antagonists targeting MRGPRX4 for the treatment of cholestatic pruritis and MRGPRX2 for mast cell mediated disorders.
Acquired
Acquired by Allergen
Specialty pharmaceutical company focused on urological and women's health products
Acquired
Acquired by Abbott
Developer of MitraClip for catheter-based edge-to-edge mitral valve repai
Premier medical device incubator focused on developing patient-driven solutions to persistent medical problems.
Implantable remote monitoring device for heart failure patients.
The Foundry is the premier medical device company incubator for inventors to rapidly transform their concepts into companies.
IPO/Acquired
NASDAQ:FOXH
Acquired by Coviden
Medical devices for the treatment of coronary and peripheral arterial disease
Developing a portfolio of clinical-stage small molecule superoxide dismutase mimetics for the treatment of mucositis, cancer and fibrosis
Non-absorbed, polymer-based pharmaceuticals for the selective gastro-intestinal elimination of substances
IPO/Acquired
Acquired by Sandoz Pharmaceuticals
Products and services based on proprietary technology to implement human gene therapy
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Small molecule therapeutics that mimic the action of carbohydrates to treat inflammatory and infectious diseases
Biopharmaceutical company developing seralutinib for the treatment of pulmonary arterial hypertension (PAH).
IPO/Public
Johnson & Johnson
Endometrial ablation system for the treatment of excessive uterine bleeding
Acquired
Acquired by Inverness Medical
INRatio anti-coagulation monitor for patient self-testing
Acquired
Acquired by Eli Lilly and Company
Private biopharmaceuticals company pioneering the discovery of novel drugs using its expertise in Transient Receptor Protocols in ion channels and molecular regeneration
IPO/Acquired
NASDAQ: HPTX
Acquired by Horizon Pharma
Specialty therapeutics company focused on gastrointestinal and hepatology diseases and programs
Developing IMR-687, an IND-ready PDE9 (phosphodiesterase 9) inhibitor for sickle cell disease
Lymphokines for therapeutic use as anti-cancer agents supporting the human immune system
IPO/Acquired
NASDAQ: IMMU
Acquired by Gilead Sciences (NASDAQ: GILD)
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer.
Clinical-stage biotechnology company developing a therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer.
IPO/Acquired
Acquired by Bristol Myers Squibb
Biopharmaceutical company focused on novel antibody-based products for serious hospital-associated bacterial and fungal infections
Acquired
Acquired by BioMarin Pharmaceutical
Biotechnology company developing new medicines to treat rare disorders of calcification with initial focus on enzyme replacement therapy for devastating and debilitating rare diseases that largely impact infants, children and young adults.
IPO/Acquired
NYSE:PHG
Acquired by Royal Philips
A medical device company that is developing a novel, minimally invasive medical device for the treatment of peripheral arterial disease (PAD).
IPO/Acquired
NASDAQ: ITMN
Acquired by Roche Holding AG
Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.
Developing device-based therapies for soft-tissue injuries of the spine
Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
Acquired
Acquired by Novo Nordisk
Inversago Pharma specializes in the development of new therapies focusing on CB1blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
IPO/Acquired
Acquired by Intercell AG
Vaccines and immune system stimulants delivered through novel needle-free transcutaneous immunization
Ophthalmic probes and diode laser-based systems
Acquired
Acquired by Alcon
Developing products for the treatment of eye diseases
IPO/Acquired
NASAQ: KRRO
Merged with Frequency Therapeutics
A preclinical-stage biopharma company that is developing novel RNA editing therapeutics to treat genetically-driven disease. Korro’s OPERA platform coopts the body’s ADAR system to make targeted edits to a single RNA base.
Collaborates with client hospitals and community physicians in the development and management of a proven disease management program for the care of gastroesophageal reflux disease (GERD)
LeonaBio is dedicated to the development of novel therapeutics for diseases with high unmet needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patient’s lives.
Biopharmaceutical company that has harnessed the power of genetics for drug discovery.
Tissue culture media, immunodiagnostics and test kits for the life sciences research field
Utilizes a proprietary nanotechnology platform to develop precisely engineered products in the materials and life sciences sectors
IPO/Acquired
NASDAQ: LOXO
Acquired by Eli Lilly & Co.
Biopharma company developing targeted cancer therapies for genetically-defined patient populations
Acquired
Acquired by Shire
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health.
Acquired
Acquired by NewLink Genetics
Developing a novel therapeutic for the rare disease Creatine Transporter Deficiency, an inborn error of metabolism
Lungpacer Medical Inc. is developing a novel therapeutic solution for preserving or restoring the integrity and strength of the diaphragm muscle in critically ill patients who require mechanical ventilation.
Advancing potential breakthrough medicines for rare endocrine diseases of substantial medical need with validated molecular targets.
Oncology company focused on the clinical development of novel therapies for cancer
Next-generation percutaneous left ventricular assist device targeting high-risk percutaneous coronary intervention and cardiogenic shock.
Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood and solid tumor cancers.
Biopharmaceutical company that is creating the next generation of antibody drug conjugates using its Fleximer-ADC technology
Metacrine is a biotech company developing innovative therapeutics for liver, gastrointestinal, and metabolic diseases. The lead program is a best-in-class FXR agonist for multiple diseases, including non-alcoholic steatohepatitis (NASH).
Medical device start-up company focused on women's health care
Biopharmaceutical company focused on microRNA (miRNA)-directed oncology therapies
Mirum Pharmaceuticals, Inc. is a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins by creating a platform that designs small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable.
Acquired
Acquired by Allergan
Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases.
Implantable shock absorber (ISA) that unloads the knee, relieves pain, and improves function for patients with osteoarthritis.
IPO/Public
IPO/Public Gilead Sciences
Biopharmaceutical company focused on small molecule therapeutics for the treatment of cardiovascular disorders.
Research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet needs.
Patient monitoring instruments and disposable supplies for use in surgery
Developing a personal use device to treat migraine using transcranial magnetic stimulation
Developing implantable devices for the treatment of neurological disorders by responsive brain stimulation
Next generation high frequency spinal cord stimulation for the treatment of chronic pain
Leading Chinese producer of active pharmaceutical ingredients (API) for global markets
Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
IPO/Acquired
NASDAQ: NITE
Acquired by Biogen
Private biopharmaceutical company focused on the development of therapies for retinal dystrophies.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer.
Acquired
Cytyc Corporation
Cytyc
Innovative medical devices to improve the quality and cost-effectiveness of healthcare for women
China's leading speciality pharmaceutical developer
Acquired
Aytu BioScience, Inc.
Nuelle™ is a sexual wellness company focused on delivering groundbreaking solutions made specifically for women, backed by science that promote individual vitality and healthy relationships.
ObsEva is a clinical stage biopharmaceutical company focusing on the development of a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth.
Acquired
Acquired by Allergan
Developing a novel treatment for Dry Eye, a disease affecting millions of people worldwide
IPO/Acquired
NASDAQ: OMTH
Acquired by Astrazeneca
Emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery.
IPO/Acquired
NASDAQ: OREX
Acquired by Nalpropion Pharmaceuticals
Pharmaceutical company focused on development of treatments for obesity.
San Diego-based clinical stage biopharmaceutical company focused on the development of small molecule inhibitors that can overcome resistance mechanisms in cancer.
Acquired
Acquired by Eli Lilly & Company
Specialized endosurgery devices and instruments for orthopedic and general surgery
Biopharmaceutical company focused on the development and commercialization of novel first in class therapeutic dimer conjugates.
IPO/Acquired
Acquired by: GILEAD
Ouro Medicines is a clinical-stage biopharmaceutical company focused on becoming the leading "immune reset" company, targeting chronic immune-mediated diseases through cell-depleting therapies.
IPO/Acquired
NASDAQ: OYST
Acquired by Viatris
Oyster Point is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
Acquired
Acquired by Ikena
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
Panacea Medical Technologies is a professional health care company, nurturing a culture of innovation and clinical solutions for diagnosis of cancer. Also premier manufacturer for digital radiography and high end mammography equipment.
IPO/Acquired
NASDAQ: PRTK
Acquired by Novo Holdings and Gurnet Point Capital
Specialty pharmaceutical company focused on addressing therapeutic needs in the fields of psychiatry and sleep medicine
Acquired
Acquired by LEO Pharma
Specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products
Acquired
Acquired by LabCorp
Innovative genomic technologies to solve fundamental challenges in oncology
IPO/Acquired
Acquired by Celgene Corporation
Biotechnology company focused on acquiring, developing and commercializing innovative products in hematology and oncology.
Focused on discovery and development of therapeutic fusion proteins based on its proprietary Elastin-Like Polypeptide (ELP) technology
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases.
Developing highly accurate, noninvasive diagnostic products for informed cancer management
IPO/Acquired
NASDAQ: RNA
Acquired by BioMarin
Biopharmaceutical company developing therapeutics for orphan genetic diseases with a focus on neuromuscular disorders
Discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network
Acquired
Acquired by Cytyc Corporation
Internal radiation delivery systems for the treatment of solid cancerous tumors
Acquired
Acquired by Emalex
Developing ecopipam, a dopamine D-1 antagonist, for the treatment of Tourette's syndrome, a neurological disorder manifested by motor and phonic tics.
Acquired
Acquired by Shionogi
Qpex Biopharma is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings.
IPO/Acquired
NASDAQ: RARX
Acquired by UCB
Developing a new class of drugs with the diversity and specificity of antibodies, coupled with the oral bioavailability of small molecules
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity.
RedRidge Bio is a biotech company developing transformative therapies for cancer and autoimmune diseases.
Acquired
Acquired by Novartis AG
Clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases.
Acquired
Acquired by Boston Scientific
Percutaneous radiofrequency procedure to ablate the basivertebral nerve for the treatment of chronic axial low back pain.
Biopharmaceutical company licensing and developing drugs to treat fibrosis.
IPO/Acquired
NASDAQ: RPRX (old)
Acquired by Allergan
Biopharmaceutical company developing therapeutic drugs and formulations designed to treat hormonal and reproductive system disorders.
Acquired
Acquired by Tiger Aesthetics Medical, LLC
Minimally invasive procedure to effectively target the root cause of cellulite.
Biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases
Clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders
Acquired
Acquired by Smith & Nephew
Medical device start-up company on mission to advance the treatment of rotator cuff disease
A clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways.
A clinical stage biopharmaceutical company focused on rare respiratory diseases.
IPO/Acquired
NASDAQ: SGEN
Acquired by Pfizer
Biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Developing broadly enabling chemical sensing technologies based on fluorescence sensing with initial products for implantable glucose sensors and metabolic rate monitors
IPO/Public
NASDAQ: SNTI
Dynamics Special Purpose Corp.
Focused on use of synthetic biology techniques to engineer mammalian cells for a wide variety of applications.
Bioactive membranes and other separation technologies for the chemical processing and pharmaceutical fields
Implantable neuromodulation device targeting the vagus nerve to treat chronic inflammatory diseases, with an initial indication for rheumatoid arthritis.
A development stage biotechnology company based in Seattle WA and San Diego CA that is establishing itself as a leader in next generation genomic medicine.
IPO/Acquired
NASDAQ: SLTM
Acquired by Valeant
Developing transformational aesthetic products, procedures and services.
IPO/Public
William Demant Holding
A new generation of hearing aids based on patented digital signal processing technology
Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn’s disease and ulcerative colitis.
Medical device company focused on degenerative disc disease, vertebral compression fractures, and nucleus replacement
Acquired
Acquired by Olympus Corporation
Medical device company focused on bronchoscopic treatment for emphysema
SpliceBio is a biotechnology company exploiting Protein Splicing to develop next generation gene therapies.
Medical device incubator focused on three novel ophthalmic devices.
Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.
IPO/Public
NASDAQ: XERS
Xeris Pharmaceuticals
Global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.
NASDAQ: VIRX
Merger between Sunesis and Viracta
Clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics
IPO/Acquired
NASDAQ: SPUG
Merged with Astex Therapeutics
Pharmaceutical company dedicated to the discovery and development of novel cancer therapies.
IPO/Public
IPO/Public
NASDAQ: SUPN
Leveraging expertise in product development and oral drug delivery to develop unique specialty pharmaceutical products
IPO/Acquired
NASDAQ: SURF
Acquired by Coherus
Focused on developing novel oncology-focused antibody therapeutics against series of targets that modulate elements at the boundary of the innate and adaptive immune systems
Acquired
Acquired by Johnson & Johnson
Medical devices for secure, rapid vessel sealing and transection for use in open and laparoscopic surgery
Leverages the most advanced technology platform available for the creation of synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease
Clinical stage biopharmaceutical company focused on development of novel therapeutics for cancer and age-related macular degeneration.
Precision therapy company leveraging its ‘click-2-release’ technology platform to unlock full potential of systemic therapies by improving therapeutic window and improving standard of care for patients suffering from severe diseases including cancer.
A clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.
IPO/Acquired
NASDAQ: TSRO
Acquired by GlaxoSmithKline
Oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and commercializing safer and more effective therapeutics
Developing a novel biologic therapy for achondroplasia, the most common form of dwarfism
Acquired
Acquired by Sanofi
Tidal Therapeutics is a preclinical biotech company focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases.
Acquired
Acquired by Abbott Labs
A clinical stage medical device company developing a novel catheter based mapping system used for guiding cardiac ablation procedures for the treatment of arrhythmias like atrial fibrillation
Acquired
Acquired by Medtronic
New class of intervention for the treatment of vascular diseases and other disorders
Discovering biased GPCR ligands that unlock new biology and avoid side effects as medicines for cardiovascular diseases, pain and inflammation
Trevi Therapeutics develops nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia
IPO/Acquired
NASDAQ/TSX: TRIL
Acquired by Pfizer
Clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
IPO/Acquired
NASDAQ: TRIV
Acquired by Endologix
Developing endovascular repair devices to treat abdominal aortic aneurysms
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment.
Acquired
Acquired by Merz
=
Developer of a novel ultrasound-based medical device platform for the expanding non-invasive aesthetic treatments market
Acquired
Acquired by McKesson
Comprehensive development, implementation and management solutions for radiation oncology centers
Acquired
Merck Sharp & Dohme
A clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases.
Structural biology and organic chemistry-based human therapies and drugs
Acquired
NYSE: BSX
Acquired by Boston Scientific
Developing minimally invasive and motion preservation technologies for disorders of the spine
Acquired
Acquired by Royal Philips
Vesper Medical is shaping the future of treating deep venous disease through the creation of a next-generation, modular, and uniquely engineered venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins and provides the ability to customize therapy.
A biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders.
IPO/Acquired
NASDAQ: VTAE
Acquired by Allergan
Drug discovery company developing optimized drugs using proprietary computational drug design platform
Biotech company built around a Phase 2/3 ready asset from NIH / NCATS, cyclodextrin, for the treatment of Niemann-Pick C (NPC)
Developing a next generation integrated imaging and ablation system for cardiac electrophysiologists
The first all-in-one, mobile, wireless, and hands-free wearable breast pump.
Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers.
Acquired
Acquired by Valeant Pharmaceuticals
Specialty pharmaceutical company focused on disorders of the central nervous system
Clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xoc Pharmaceuticals is an early-stage, biopharmaceutical company focused on the development of innovative therapeutics. The Company designs novel products “from the ground up” by leveraging information on existing compounds with established pharmacological and clinical history and using its proprietary design and development process to address unmet medical needs, primarily in the CNS disease space. Xoc’s initial product programs are in migraine prevention and Parkinson’s disease maintenance.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response.
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients around the world.
Acquired
Acquired by Novartis
Clinical stage biotechnology company progressing novel & differentiated therapies for inflammatory and allergic diseases, using both oral and topical routes of delivery.
IPO/Acquired
NASDAQ: ZSAN
Acquired by Zosano Pharma Corporation
Painless, convenient transdermal patient administration of therapeutic proteins and vaccines